ROR[gamma]t inhibitors suppress TH17 responses in inflammatory arthritis and inflammatory bowel disease

• Published in: Journal of allergy and clinical immunology 2016-03, Vol.137 (3), p.960
• Main Authors: de Wit, Jelle, Al-Mossawi, M Hussein, Hühn, Michael H, Arancibia-Cárcamo, Carolina V, Doig, Karen, Kendrick, Benjamin, Gundle, Roger, Taylor, Peter, Mcclanahan, Terri, Murphy, Erin, Zhang, Hongjun, Barr, Ken, Miller, J Richard, Hu, Xiao, Aicher, Thomas D, Morgan, Rodney W, Glick, Gary D, Zaller, Dennis, Correll, Craig, Powrie, Fiona, Bowness, Paul
• Format: Article
• Language: English
• Subjects: Arthritis; Cytokines; Inflammatory bowel disease; Inflammatory diseases; Lymphocytes
• ISSN: 0091-6749; 1097-6825
• DOI: 10.1016/j.jaci.2015.09.048

To the Editor: Increased frequencies of T-helper cells producing the proinflammatory cytokine IL-17A (TH17) have been reported in ankylosing spondylitis (AS), rheumatoid arthritis (RA), psoriatic arthritis (PsA), and inflammatory bowel disease (IBD).1 Genome-wide association studies have linked multiple TH17-associated genes, including IL23R, with AS, psoriasis, and IBD, further supporting a common pathogenic role for the IL-17/IL-23 axis in these diseases.2 Neutralizing IL-17A with mAbs has shown efficacy in AS and PsA,3 and some benefit in RA,4 but has proved ineffective and possibly deleterious in patients with IBD.5 There is therefore a need for new therapies, including small-molecule inhibitors, that target type 17 immune responses. [...]we analyzed the efficacy of the inhibitors on T cells obtained after 2-week culture of synovial tissue explants from patients with RA (see Fig E10 in this article's Online Repository at www.jacionline.org).